Global Head Sterility Assurance, Cell and Gene Technologies, Lonza Biologics
David Churchward joined the global quality team of Lonza's cell and gene technologies (CGT) business unit in February 2022. In his current role he is responsible for sterility assurance standards for manufacture of cell therapies and viral vector products across the Lonza CGT network.
David was previously a GMP inspector with the UK MHRA for 17 years, with his most recent role including responsibility for regulatory collaboration and strategic direction of the GxP inspectorate. He also lead implementation of innovative compliance initiatives and provided GMP expertise to the MHRA’s Innovation Office for new products and technologies.
David has extensive experience of international regulatory harmonisation, previously serving as a member of the PIC/S Executive Bureau and Committee of Officials, sub-committee for GMP Harmonisation and delegate to the ICH Assembly.